Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash from Financing Activities (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Cash from Financing Activities readings, the most recent being $123000.0 for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 26.8% to $123000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $101.6 million, a 28529.58% increase, with the full-year FY2025 number at $101.6 million, up 28529.58% from a year prior.
  • Cash from Financing Activities hit $123000.0 in Q4 2025 for Aligos Therapeutics, up from -$53000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $101.7 million in Q1 2025 to a low of -$177000.0 in Q2 2025.
  • Median Cash from Financing Activities over the past 5 years was $89000.0 (2021), compared with a mean of $13.5 million.
  • Biggest five-year swings in Cash from Financing Activities: crashed 1800.0% in 2024 and later surged 535584.21% in 2025.
  • Aligos Therapeutics' Cash from Financing Activities stood at $552000.0 in 2021, then plummeted by 78.08% to $121000.0 in 2022, then surged by 72574.38% to $87.9 million in 2023, then tumbled by 99.89% to $97000.0 in 2024, then increased by 26.8% to $123000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $123000.0 (Q4 2025), -$53000.0 (Q3 2025), and -$177000.0 (Q2 2025) per Business Quant data.